NasdaqGS - Nasdaq Real Time Price USD

LAVA Therapeutics N.V. (LVTX)

Compare

1.0300

+0.0411

(+4.16%)

At close: December 20 at 4:00:03 PM EST

1.0900

+0.06

(+5.83%)

After hours: December 20 at 7:32:33 PM EST

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266, for hematologic malignancies, and a $5.0 million milestone payment from Johnson and JohnsonCash runway extended into 2027, based on a cash balance of $78.9 million, as of September 30, 2024 UTRECHT, The Neth

GlobeNewswire 11 days ago

LVTX
+4.16%
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation DetailsFormat: Fireside ChatDate: Monday, September 9, 2024T

GlobeNewswire 3 months ago

LVTX
+4.16%
LAVA Reports Second Quarter 2024 Financial Results and Business Update

Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for LAVA-1207Next data update for LAVA-1207 program expected in Q4 2024Strong balance sheet with cash of $86.8 million supports runway into mid-2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-onc

GlobeNewswire 3 months ago

LVTX
+4.16%
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Presentation Details Format: Fireside Chat Date: Tu

GlobeNewswire 5 months ago

LVTX
+4.16%
LAVA Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST. All relevant documents and information relating to the annual general meeting, including the notice and agenda for

GlobeNewswire 6 months ago

LVTX
+4.16%
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Presentation Details Format: Fireside

GlobeNewswire 6 months ago

LVTX
+4.16%
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1LAVA-1266 on track for Q2 2024 IND submissionStrong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Compa

GlobeNewswire 6 months ago

LVTX
+4.16%
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. Presentation Details Format: Fireside

GlobeNewswire 7 months ago

LVTX
+4.16%
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint

LAVA Therapeutics ( NASDAQ:LVTX ) Full Year 2023 Results Key Financial Results Net loss: US$42.0m (loss widened by 32...

Simply Wall St. 8 months ago

LVTX
+4.16%
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024In March 2024, Pfizer paid LAVA $7 million for achieving a clinical milestone for EGFRd2 (PF-08046052/formerly LAVA-1223) LAVA 1266 tracking to Q2 2024 IND submission Strong balance sheet with cash of $95.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage

GlobeNewswire 8 months ago

LVTX
+4.16%
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Milestone triggered by clinical progress in Phase 1 study, initiated in Q4 2023UTRECHT, The Netherlands and PHILADELPHIA, March 05, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Pfizer has achieved a clinical development milestone for PF-08046052 (formerly SGN-EGFRd2 /LAVA-1223), prompting the first milestone

GlobeNewswire 9 months ago

LVTX
+4.16%
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembr

GlobeNewswire 10 months ago

LVTX
+4.16%

Performance Overview

Return	LVTX	S&P 500
YTD	-34.81%	+24.34%
1-Year	-31.79%	+24.38%
3-Year	-80.19%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

LAVA Therapeutics N.V. (LVTX)

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LAVA Reports Second Quarter 2024 Financial Results and Business Update

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

LAVA Announces Annual Meeting of Shareholders

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Performance Overview